Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**3-aminobenzamide** is a small molecule inhibitor of the enzyme poly(ADP-ribose) polymerase (PARP), a key regulator of DNA repair, transcription control, and programmed cell death. By mimicking the structure of NAD+, 3-aminobenzamide competitively binds to the catalytic domain of PARP, inhibiting its activity, thereby preventing DNA repair and leading to NAD+ and ATP depletion in cells with activated PARP, which can result in cell death. This mechanism underlies its use as a tool compound in research on DNA damage response, radiosensitization, neuroprotection, and oxidative stress injury, and it has been investigated for potential anticancer and organ-protective applications[1][2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-aminobenzamide.